Skip to main content
Equibles
TCRT logo

TCRT · Alaunos Therapeutics, Inc. · Metrics

Track TCRT — free

Use TCRT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research TCRT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.74 -0.10 (-5.43%) At close · Nov 6 Q1 2023 earnings call transcript
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Based on the current cash forecast and the Company's dependence on its ability to obtain additional financing to fund its operations after the current resources are exhausted, about which there can be no certainty, management has determined that the Company's present capital resources will not be sufficient to fund its planned operations for at least one year from the issuance date of the financial statements which raises substantial doubt as to the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 14, 2026
Market Cap
$4.42M
Shares
2.54M
Volume · Nov 6 101.46K Avg daily vol (3M) 7.43M

TCRT metrics

79 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.74
Market cap
$4.42M

Price action

23 metrics
Price change (1W)
-2.6%
Price change (30D)
+119.5%
Price change (3M)
-7.5%
Price change (6M)
-31.1%
Price change (YTD)
-43.0%
Price change (1Y)
-26.7%
Trailing year
Price change (5Y)
—
52-week high
$4.36
52-week low
$0.74
Change from 52-week high
-57.8%
Change from 52-week low
+147.8%
Annualized volatility
215.0%
Annualized volatility (3M)
404.6%
Implied volatility (30D)
—
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
1.0
RSI (14D)
48.6
Price vs SMA 50
+12.1%
Price vs SMA 200
-20.3%
Avg volume (3M)
7.43M
Relative volume
0.0
Average dollar volume
$19.62M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
2.54M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
1,516.8×
reciprocal yield 0.1%
EV / EBITDA
—
EV / EBIT
—
P / sales
1,558.2×
reciprocal yield 0.1%
P / book
7.2
reciprocal yield 13.9%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-85.8%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
2,307.5×
reciprocal yield 0.0%
EV / revenue historical average (5Y)
2,135.4×
reciprocal yield 0.0%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2023-05-10

Profitability

9 metrics
Gross margin
—
Operating margin
-135,266.7%
Trailing 12 months
Net margin
-133,666.7%
Gross profit (TTM)
—
Operating profit (TTM)
−$4.06M
Net income (TTM)
−$4.01M
Trailing 12 months
Diluted EPS (TTM)
$-1.90
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.00
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-1.85
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-1.82
Operating cash flow per diluted share (TTM)
$-1.28
Free cash flow per diluted share (TTM)
$-3.10
Capital expenditures per diluted share (TTM)
$0.00
R&D per diluted share (TTM)
$0.75
Stock compensation per diluted share (TTM)
$0.42
Book value per share
$0.92

Growth

11 metrics
Revenue growth YoY
-50.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$3,000
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+45.1%
Year over year · more shares
Revenue CAGR (3Y)
-88.0%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-615.0%
Return on assets
-264.5%
Debt / equity
0.0
Current ratio
0.8
EBITDA (TTM)
−$50.85M
Free cash flow (TTM)
—
Quick ratio
0.8
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$124,000
Latest balance sheet
Cash & equivalents
$124,000
Total assets
$1.52M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$2.73M
Capital expenditures (TTM)
$0
R&D (TTM)
$1.65M
SG&A (TTM)
—
Stock compensation (TTM)
$931,000
R&D / revenue
54,866.7%
Stock compensation / revenue
31,033.3%

Ownership (13F)

9 metrics
13F filers
29
13F filer change QoQ
0
Institutional ownership
3.6%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
0.1%
Private-fund adviser ownership
0.1%
Active holders' share change QoQ
-62.8%
Holder tenure
10.1
Price vs estimated holder cost
-29.1%

Ownership (registered funds)

1 metrics
Index-fund ownership
1.4%

Short interest

3 metrics
Short interest
32.2%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
62 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1107421 CUSIP 98973P309 13F (30d) 18 filings 11 filers Visit website Investor relations